2025 San Francisco Lung Cancer Conference

San Francisco, CA US
May 2, 2025 to May 3, 2025

This CME-accredited activity 2025 San Francisco Lung Cancer Conference features leading experts in thoracic malignancies who will provide a comprehensive overview of current and emerging strategies for management of lung cancer (NSCLC, SCLC). The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with lung cancer. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for thoracic oncology. Expert faculty will aim to place the role of diagnostics, biomarkers and different therapeutic agents in clinical context and discuss how to utilize these tests and therapies to effectively contribute to patient care. 

Target Audience

  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists,
  • Pathologists
  • Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists

ORGANIZING COMMITTEE

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Jonathan Riess, MD, MS - UC Davis 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Review potentially actionable molecular abnormalities in lung cancer, and the appropriate testing and treatment for actionable alteration.
  2. Summarize efficacy and toxicities of immune checkpoint inhibitors, targeted therapy, and other chemotherapy agents in management of management of lung cancer.
  3. Identify the role of perioperative systemic therapy options in curative-intent treatment of NSCLC, including the role of chemotherapy, immune checkpoint inhibitors and targeted therapy.
  4. Integrate emerging evidence of cutting edge developments in precision oncology into treatment paradigms for treatment of thoracic malignancies.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.
Course opens: 
11/07/2024
Course expires: 
08/02/2025
Event starts: 
05/02/2025 - 2:00pm PDT
Event ends: 
05/03/2025 - 3:00pm PDT
Cost:
$350.00
Add to calendar: 

Day 1 - May 2nd, 2025

All times are listed in Pacific Daylight Time (PDT)

02:00 PM - 02:45 PM  Registration, Networking, & Exhibits

02:45 PM - 03:00 PM  Opening Remarks

03:00 PM - 04:30 PM  Session 1: Progress in Targeted Therapy for Lung Cancer

Session Chairs: Christina Baik, MD, MPH

03:00 PM - 03:15 PM  Keynote Speech: Evolution of Targeted Therapy in EGFR mutated NSCLC - 

03:15 PM - 03:30 PM  Optimal Sequencing of Therapy in EGFR mutant NSCLC - 

03:30 PM - 03:45 PM  Targeting HER2 in NSCLC - Christina Baik, MD, MPH

03:45 PM - 04:00 PM  EGFR Exon 20 ins and Uncommon Mutations in NSCLC - Jonathan Riess, MD, MS

04:00 PM - 04:15 PM  Targeting other Uncommon Oncogene Drivers (MET, RET, and others) - Nathaniel Myall, MD

04:15 PM - 04:30 PM  Panel Discussion

04:30 PM - 05:30 PM  Session 2: New Targets and Treatments in Oncogene Driven Lung Cancer

Session Chairs: Mohana Roy, MD

04:30 PM - 04:45 PM  Keynote: Beyond the Usual Suspects: Uncovering Novel Resistance Mechanisms to Targeted Therapy - 

04:45 PM - 05:00 PM  Evolution of ALK and ROS1 treatments in Lung Cancer - Mohana Roy, MD

05:00 PM - 05:15 PM  Next Generation KRAS Inhibitors - Michael Cheng, MD

05:15 PM - 05:30 PM  Panel Discussion

05:30 PM - 06:15 PM  Reception, Networking, & Exhibits 

 

Day 2 - May 3rd, 2025

07:00 AM - 07:30 AM  Breakfast & Exhibits

07:30 AM – 07:35 AM  Welcome

07:35 AM – 08:00 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD

08:00 AM - 09:00 AM  Session 3: Immunotherapy and ADCs in Advanced Lung Cancer: What's Next? 

Session Chairs: Tianhong Li, MD, PhD

08:00 AM - 08:15 AM  New Biomarkers for IO Agents in Lung Cancer - 

08:15 AM - 08:30 AM  Cellular Therapies in Lung Cancer - Greg Allen, MD, PhD

08:30 AM - 08:45 AM  Novel IO Agents in NSCLC - Tianhong Li, MD, PhD

08:45 AM - 09:00 AM  Panel Discussion

09:00 AM - 10:30 AM  Session 4: Multimodality Treatment in Lung Cancer

Session Chairs: Heather Wakelee, MD, FASCO

09:00 AM - 09:30 AM  Keynote Speech: Optimizing Perioperative Therapy in Early Stage / Locally Advanced NSCLC - Heather Wakelee, MD, FASCO

09:30 AM - 09:45 AM  Multistation N2 Disease: Chemo-IO -> Surgery is the Best Treatment - 

09:45 AM - 10:00 AM  Multistation N2 Disease: Chemoradiation -> IO - 

10:00 AM - 10:15 AM  Integrating Targeted Therapy in Early Stage and Locally Advanced NSCLC - 

10:15 AM - 10:30 AM  Panel Discussion

10:30 AM - 11:00 AM  Break & Exhibits

11:00 AM - 12:00 PM  Session 5: New Biomarkers in Lung Cancer

Session Chairs: 

11:00 AM - 11:15 AM  New Biomarkers in Immunotherapy - 

11:15 AM - 11:30 AM  New Biomarkers in Small Cell Lung Cancer and other Neuroendocrine Tumors - Julien Sage, PhD

11:30 AM - 11:45 AM  Circulating Tumor DNA in Lung Cancer: Next Steps -  

11:45 AM - 12:00 PM  Panel Discussion

12:00 PM - 01:00 PM  Lunch & Exhibits

01:00 PM - 02:15 PM  Session 6: Latest and Greatest in Squamous Lung Cancer, Small Cell Lung Cancer, & Thymoma / Mesothelioma

Session Chairs: Kim-Son Nguyen, MD, MPA

01:00 PM - 01:15 PM  Advances in SCLC and other Neuroendocrine Tumors - 

01:15 PM - 01:30 PM  Advances in the Treatment of Thymic Malignancies and Mesothelioma - 

01:30 PM - 01:45 PM  ABCs of ADCs in Lung Cancer - 

01:45 PM - 02:00 PM  New Targets in Squamous NSCLC - 

02:00 PM - 02:15 PM  Panel Discussion

02:15 PM - 03:00 PM  Session 7: Important Patient Populations in Lung Cancer

Session Chairs: Deepti Behl, MD

02:15 PM - 02:30 PM  Advances in CNS Disease in Lung Cancer - Seema Nagpal, MD

02:30 PM - 02:45 PM  Special Considerations for Treatment of Lung Cancer in Older Adults - 

02:45 PM - 03:00 PM  Panel Discussion

03:00 PM  Adjourn

Grand Hyatt at SFO
55 S McDonnell Rd
San Francisco, CA 94128
United States

Faculty information coming soon

Session Chair(s)

Christina Baik, MD MPH

has a financial relationship (Other) with TurningPoint;.
has a financial relationship (Other) with Jansen;.
has a financial relationship (Independent contractor) with Daiichi;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Other) with Nuvalent;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Boehringer;.
has a financial relationship (Other) with Daiichi;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Other) with Ellipses;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Other) with Blueprint;.
has a financial relationship (Other) with BlackDiamond;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Boehringer;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Jansen;.

DEEPTI BEHL, M.D.

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with boehringer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with janssen;.
has a financial relationship (Professional Services) with AZ;.

Kim-Son Nguyen

has no relevant financial relationships to disclose at this time.

Surbhi Singhal, MD

has a financial relationship (Other) with Meetings Events and Conference Coordinators;.
has a financial relationship (Other) with Physician Education Resource;.

Heather Wakelee, MD

has a financial relationship (Other) with BMS, Genentech/Roche; Merck; AstraZeneca;.
has a financial relationship (Independent contractor) with IOBiotech, Mirati;.
has a financial relationship (Grant Or Contract) with AstraZeneca /Medimmune; Bayer; BMS; Genentech/Roche; Helsinn; Merck; SeaGen; Xcovery;.
Speaker/Topic Presenter(s)

Christina Baik, MD MPH

has a financial relationship (Independent contractor) with Daiichi;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Other) with Nuvalent;.
has a financial relationship (Other) with TurningPoint;.
has a financial relationship (Other) with Jansen;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Boehringer;.
has a financial relationship (Other) with Daiichi;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Other) with Blueprint;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Other) with Ellipses;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Jansen;.
has a financial relationship (Other) with BlackDiamond;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Boehringer;.

Collin Blakely, MD/PhD

has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Verastem;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Puma;.
has a financial relationship (Grant Or Contract) with Mirati;.

Julien Sage

has no relevant financial relationships to disclose at this time.

Surbhi Singhal, MD

has a financial relationship (Other) with Meetings Events and Conference Coordinators;.
has a financial relationship (Other) with Physician Education Resource;.

Heather Wakelee, MD

has a financial relationship (Grant Or Contract) with AstraZeneca /Medimmune; Bayer; BMS; Genentech/Roche; Helsinn; Merck; SeaGen; Xcovery;.
has a financial relationship (Other) with BMS, Genentech/Roche; Merck; AstraZeneca;.
has a financial relationship (Independent contractor) with IOBiotech, Mirati;.

Available Credit

  • 8.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.